Supplementary Figure S3 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)

Key Points

• Ponatinib shows promise in treating metastatic gastrointestinal stromal tumor after imatinib failure, with improved outcomes for T670I-mutant KIT patients.
• The treatment exhibited efficacy in patients experiencing intolerance to prior therapies, highlighting its potential role in challenging cases.
• Structural analyses reveal interactions of sunitinib, regorafenib, and ripretinib with T670I-mutant KIT, offering insights into drug mechanisms.
• The phase II trial findings emphasize the need for ongoing investigation into novel therapies for resistant tumor mutations.